Literature DB >> 23122698

Bioprosthetic pulmonary valve replacement: contemporary analysis of a large, single-center series of 170 cases.

Xu-Jun Chen1, P Brian Smith, James Jaggers, Andrew J Lodge.   

Abstract

OBJECTIVE: The present study was designed to compare stented porcine and bovine pericardial valves used for pulmonary valve replacement to better define valve performance and postoperative quality of life.
METHODS: A retrospective review of all patients who underwent pulmonary valve replacement with a stented bioprosthesis from 1992 to 2008 was conducted. The medical records, imaging results, and quality of life questionnaires were analyzed. Differences in reintervention by valve type were determined using Cox proportional hazards models, controlling for subject age.
RESULTS: A total of 170 consecutive pulmonary valve replacements (73 stented porcine, group 1; 97 bovine pericardial, group 2) were reviewed. No significant differences were seen in patient age or implanted valve size between the groups. Surgical mortality was 1.2%. The median follow-up was 48.2 months and was longer for group 2. No significant difference was seen in the risk of reintervention by valve type (hazard ratio, 0.64; 95% confidence interval, 0.18-2.34; P = .51). After 39 months of follow-up, pulmonary stenosis and pulmonary insufficiency that was moderate or worse were more common in patients who had undergone pulmonary valve replacement at younger than 15 years (pulmonary stenosis, 30.9% vs 10.0%, P = .003; pulmonary insufficiency, 46.2% vs 3.8%, P < .001), regardless of valve type. All patients performed well mentally and physically on the quality of life surveys.
CONCLUSIONS: The present large series of stented bioprosthetic pulmonary valve replacements has demonstrated good results, particularly in adults, at intermediate follow-up. Freedom from reintervention was similar for the porcine and pericardial valves, and our finding did not clearly demonstrate the superiority of 1 type of valve. However, the stented bioprosthetic valves were less durable in younger patients.
Copyright © 2013 The American Association for Thoracic Surgery. Published by Mosby, Inc. All rights reserved.

Entities:  

Keywords:  26.1; 29; 35; PI; PS; PVR; RV; TOF; pulmonary insufficiency; pulmonary stenosis; pulmonary valve replacement; right ventricular; tetralogy of Fallot

Mesh:

Year:  2012        PMID: 23122698     DOI: 10.1016/j.jtcvs.2012.09.081

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  5 in total

1.  Pulmonary Valve Replacement With a Trifecta Valve Is Associated With Reduced Transvalvular Gradient.

Authors:  Brian C Gulack; Ehsan Benrashid; Robert D B Jaquiss; Andrew J Lodge
Journal:  Ann Thorac Surg       Date:  2016-08-25       Impact factor: 4.330

Review 2.  Pulmonary valve replacement after repaired Tetralogy of Fallot.

Authors:  Hideki Tatewaki; Akira Shiose
Journal:  Gen Thorac Cardiovasc Surg       Date:  2018-05-19

3.  Whether Pulmonary Valve Replacement in Asymptomatic Patients With Moderate or Severe Regurgitation After Tetralogy of Fallot Repair Is Appropriate: A Case-Control Study.

Authors:  Fengpu He; Zicong Feng; Qiuming Chen; Yiping Jiao; Zhongdong Hua; Hao Zhang; Keming Yang; Kunjing Pang; Minjie Lu; Kai Ma; Sen Zhang; Lei Qi; Guanxi Wang; Shoujun Li
Journal:  J Am Heart Assoc       Date:  2019-01-08       Impact factor: 5.501

4.  Prompt recovery after surgical treatment of pulmonary and aortic valve endocarditis in a patient with acute heart failure.

Authors:  Aikaterini Gavalaki; George Athanasopoulos; Antonios Roussakis; Michael Koutouzis; Konstantinos Perreas; Ioannis Nenekidis
Journal:  J Surg Case Rep       Date:  2022-07-04

Review 5.  Pulmonary regurgitation after repaired tetralogy of Fallot: surgical versus percutaneous treatment.

Authors:  Juan Antonio Meca Aguirrezabalaga; Jacobo Silva Guisasola; Rocío Díaz Méndez; Alain Eliott Escalera Veizaga; Daniel Hernández-Vaquero Panizo
Journal:  Ann Transl Med       Date:  2020-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.